Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder

Dialogues in Clinical Neuroscience

Volumn 16, Issue 1, 2014, Pages 63-73

  Martins de Souza, Daniel ^a,b,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biomarker; Blood; Brain; CSF; Depression; Interactomics; Major depression; Mass spectrometry; Metabolomics; NMR; Proteomics

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALDOLASE C; APOLIPOPROTEIN E; CARBONATE DEHYDRATASE II; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; CYSTATIN C; DEFORMED EPIDERMAL AUTOREGULATORY FACTOR 1; GAMMA AMINOBUTYRIC ACID RECEPTOR ASSOCIATED PROTEIN LIKE 2; GLYCOGEN SYNTHASE KINASE 3; HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1; PHENYLALANINE; PHOSPHATIDYLINOSITOL 3 KINASE; PIGMENT EPITHELIUM DERIVED FACTOR; PROSTAGLANDIN D2; PROTEIN; PROTEOME; PURINE; SYNAPSIN I; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN 1; SYNTAXIN 1B; TOCOPHEROL; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG;

ANTERIOR CINGULATE; ARTICLE; BIOMICS; BIPOLAR DISORDER; BRAIN TISSUE; CAPILLARY ELECTROPHORESIS; CEREBROSPINAL FLUID; ENERGY METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTAL CORTEX; GAS CHROMATOGRAPHY; GLYCOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERACTOME; ISOELECTRIC FOCUSING; ISOELECTRIC POINT; ISOTOPE LABELING; MAJOR DEPRESSION; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOME; METABOLOMICS; MOLECULAR INTERACTION; MONONUCLEAR CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN INTERACTOMICS; PROTEOMICS; SCHIZOPHRENIA; SHOTGUN MASS SPECTROMETRY; SYNAPTIC TRANSMISSION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; ANIMAL; PATHOPHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; DEPRESSIVE DISORDER, MAJOR; HUMANS; METABOLOMICS; PROTEOMICS;

EID: 84898921742     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. World Health Organization. Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level. Available at: http://apps.who.int/gb/ebwha/ pdf_files/EB130/B130_9-en.pdf. Updated December 1, 2011. Accessed January 7, 2014.
2. Murrough JW, Charney DS. Is there anything really novel on the anti-depressant horizon. Curr Psychiatry Rep. 2012;14:643-649.
3. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
4. Martins-de-Souza D. Comprehending depression through proteomics. Int J Neuropsychopharmacol. 2012;15:1373-1374.
5. Wilkins MR, Pasquali C, Appel RD, et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (N Y). 1996;14:61-65.
6. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975;250:4007-4021.
7. Bjellqvist B, Ek K, Righetti PG, et al. Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications. J Biochem Biophys Methods. 1982;6:317-339.
8. Gorg A, Postel W, Gunther S, et al. Approach to stationary two-dimensional pattern: influence of focusing time and immobiline/carrier ampholytes concentrations. Electrophoresis. 1988;9:37-46. of the LMU, and Prof Wagner Gattaz from the Institute of Psychiatry of the University of Sao Paulo. The author is funded by FAPESP (Sao Paulo Research Foundation, grant 2013/08711-3).
9. Hubner NC, Ren S, Mann M. Peptide separation with immobilized pI strips is an attractive alternative to in-gel protein digestion for proteome analysis. Proteomics. 2008;8:4862-4872.
10. Westermeier R, Postel W, Weser J, Gorg A. High-resolution two-dimen-sional electrophoresis with isoelectric focusing in immobilized pH gradients. J Biochem Biophys Methods. 1983;8:321-330.
11. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis. 1997;18:2071-2077.
12. Link AJ, Eng J, Schieltz DM, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol. 1999;17:676-682.
13. Filiou MD, Martins-de-Souza D, Guest PC, Bahn S, Turck CW. To label or not to label: applications of quantitative proteomics in neuroscience research. Proteomics. 2012;12:736-747.
14. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999;17:994-999.
15. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004;3:1154-1169.
16. Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002;1:376-386.
17. Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Harris LW, Bahn S. Proteomic technologies for biomarker studies in psychiatry: advances and needs. Int Rev Neurobiol. 2011;101:65-94.
18. Martins-de-Souza D, Guest PC, Rahmoune H, Bahn S. Proteomic approaches to unravel the complexity of schizophrenia. Exp Rev Proteomics. 2012;9:97-108.
19. Oliveira BM, Martins-de-Souza D. Large-scale analyses of schizophrenia proteome. Rev Psiq Clín. 2013;40:16-19.
20. Martins-de-Souza D, Guest PC, Harris LW, et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry. 2012;2:e87.
21. Kaidanovich-Beilin O, Cha DS, McIntyre RS. Crosstalk between metabolic and neuropsychiatric disorders. F1000 Biol Rep. 2012;4:14.
22. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and psychiatric disorders. Neurochem Res. 2009;34:1021-1029.
23. Stanley JA. In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders. Can J Psychiatry. 2002;47:315-326.
24. Martins-de-Souza D, Harris LW, Guest PC, Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal. 2011;15:2067-2079.
25. Filiou MD, Zhang Y, Teplytska L, et al. Proteomics and metabolomics analysis of a trait anxiety mouse model reveals divergent mitochondrial pathways. Biol Psychiatry. 2011;70:1074-1082.
26. Varadarajulu J, Schmitt A, Falkai P, Alsaif M, Turck CW, Martins-de-Souza D. Differential expression of HINT1 in schizophrenia brain tissue. Eur Arch Psychiatry Clin Neurosci. 2012;262:167-172.
27. Barbier E, Wang JB. Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level. BMC Neurosci. 2009;10:132.
28. Varadarajulu J, Lebar M, Krishnamoorthy G, et al. Increased anxiety-related behaviour in HINT1 knockout mice. BehavBrain Res. 2011;220:305-311.
29. Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Rahmoune H, Bahn S. Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. Eur Arch Psychiatry Clin Neurosci. 2012;262:657-666.
30. Johnston-Wilson NL, Sims CD, Hofmann JP, et al. Disease-specific alter-ations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry. 2000;5:142-149.
31. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evi-dence for disease-associated changes. Proteomics. 2006;6:3414-3425.
32. Hensley K, Venkova K, Christov A, Gunning W, Park J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol. 2011;43:180-191.
33. Huang JT, Leweke FM, Oxley D, et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 2006;3:e428.
34. Ditzen C, Tang N, Jastorff AM, et al. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology. 2012;37:1013-1025.
35. Martins-De-Souza D, Wobrock T, Zerr I, et al. Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry. 2010;11:719-728.
36. Carboni L, Becchi S, Piubelli C, et al. Early-life stress and antidepressants modulate peripheral biomarkers in a gene-environment rat model of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1037-1048.
37. Zhang Y, Filiou MD, Reckow S, et al. Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways. Mol Cell Proteomics. 2011;10:M111.008110.
38. Xu HB, Zhang RF, Luo D, et al. Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. Int J Neuropsychopharmacol. 2012;15:1413-1425.
39. Martins-de-Souza D. Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci. 2010;260:561-562.
40. Martins-de-Souza D, Maccarrone G, Ising M, et al. Blood mononuclear cell proteome suggests Integrin and Ras signaling as critical pathways for antidepressant treatment response. Biol Psychiatry. 2014. In press.
41. Raamsdonk LM, Teusink B, Broadhurst D, et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol. 2001; 19: 45-50
42. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via mul-tivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181-1189.
43. Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology. 2009;34:173-186.
44. Shin MH, Lee do Y, Liu KH, Fiehn O, Kim KH. Evaluation of sampling and extraction methodologies for the global metabolic profiling of Saccharophagus degradans. Anal Chem. 2010;82:6660-6666.
45. Cubbon S, Antonio C, Wilson J, Thomas-Oates J. Metabolomic applications of HILIC-LC-MS. Mass Spectrom Rev. 2010;29:671-684.
46. Rojo D, Barbas C, Ruperez FJ. LC-MS metabolomics of polar compounds. Bioanalysis. 2012;4:1235-1243.
47. Nemutlu E, Zhang S, Juranic NO, Terzic A, Macura S, Dzeja P. 18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases. Croat Med J. 2012;53:529-534.
48. Smolinska A, Blanchet L, Buydens LM, Wijmenga SS. NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review. Anal Chim Acta. 2012;750:82-97.
49. Reo NV. NMR-based metabolomics. Drug Chem Toxicol. 2002;25:375-382.
50. Harada K, Fukusaki E, Bamba T, Sato F, Kobayashi A. In vivo 15N-enrich-ment of metabolites in suspension cultured cells and its application to metabolomics. Biotechnol Prog. 2006;22:1003-1011.
51. Zamboni N, Sauer U. Novel biological insights through metabolomics and 13C-flux analysis. Curr Opin Microbiol. 2009;12:553-558.
52. Becker S, Kortz L, Helmschrodt C, Thiery J, Ceglarek U. LC-MS-based metabolomics in the clinical laboratory. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;883-884:68-75.
53. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007;26:51-78.
54. Milne SB, Mathews TP, Myers DS, Ivanova PT, Brown HA. Sum of the parts: mass spectrometry-based metabolomics. Biochemistry. 2013;52:3829-3840.
55. Garcia A, Barbas C. Gas chromatography-mass spectrometry (GC-MS)-based metabolomics. Methods Mol Biol. 2011;708:191-204.
56. Zhou B, Xiao JF, Tuli L, Ressom HW. LC-MS-based metabolomics. Mol Biosyst. 2012;8:470-481.
57. Ramautar R, Somsen GW, de Jong GJ. CE-MS for metabolomics: devel-opments and applications in the period 2010-2012. Electrophoresis. 2013;34:86-98.
58. Lei Z, Huhman DV, Sumner LW. Mass spectrometry strategies in metabolomics. J Biol Chem. 2011;286:25435-25442.
59. Dai Y, Li Z, Xue L, et al. Metabolomics study on the anti-depression effect of xiaoyaosan on rat model of chronic unpredictable mild stress. J Ethnopharmacol. 2010;128:482-489.
60. Zheng S, Yu M, Lu X, et al. Urinary metabonomic study on biochemical changes in chronic unpredictable mild stress model of depression. Clin Chim Acta. 2010;411:204-209.
61. Zhang F, Jia Z, Gao P, et al. Metabonomics study of urine and plasma in depression and excess fatigue rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Mol Biosyst. 2010;6:852-861.
62. Wang X, Zeng C, Lin J, et al. Metabonomics approach to assessing the modulatory effects of St John's wort, ginsenosides, and clomipramine in experimental depression. J Proteome Res. 2012;11:6223-6230.
63. Kaddurah-Daouk R, Yuan P, Boyle SH, et al. Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. Sci Rep. 2012;2:667.
64. Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC. A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry. 2007;22:418-423.
65. Steffens DC, Wei J, Krishnan KR, et al. Metabolomic differences in heart failure patients with and without major depression. J Geriatr Psychiatry Neurol. 2010;23:138-146.
66. Zheng P, Gao HC, Li Q, et al. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J Proteome Res. 2012;11:1741-1748.
67. Zheng P, Wang Y, Chen L, et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol Cell Proteomics. 2013;12:207-214.
68. Kaddurah-Daouk R, Boyle SH, Matson W, et al. Pretreatment metabo-type as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. TranslPsychiatry. 2011;1.pii:e26.
69. Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiatry. 2013;3:e223.
70. Martins-de-Souza D. Translational strategies to schizophrenia from a proteomic perspective. Transl Neurosci. 2012;3:300-302.
71. Coulombe B. Mapping the disease protein interactome: toward a molecular medicine GPS to accelerate drug and biomarker discovery. J Proteome Res. 2011;10:120-125.
72. Williamson MP, Sutcliffe MJ. Protein-protein interactions. Biochem Soc Trans. 2010;38:875-878.
73. Chen J, Zhou J, Sanders CK, Nolan JP, Cai H. A surface display yeast two-hybrid screening system for high-throughput protein interactome mapping. Anal Biochem. 2009;390:29-37.
74. Scifo E, Szwajda A, Debski J, et al. Drafting the CLN3 protein interac-tome in SH-SY5Y human neuroblastoma cells: a label-free quantitative pro-teomics approach. J Proteome Res. 2013;12:2101-2115.
75. Van Leene J, Stals H, Eeckhout D, et al. A tandem affinity purification-based technology platform to study the cell cycle interactome in Arabidopsis thaliana. Mol Cell Proteomics. 2007;6:1226-1238.
76. Markham K, Bai Y, Schmitt-Ulms G. Co-immunoprecipitations revisited: an update on experimental concepts and their implementation for sensitive interactome investigations of endogenous proteins. Anal Bioanal Chem. 2007;389:461-473.
77. Bonfiglio JJ, Maccarrone G, Rewerts C, et al. Characterization of the B-Raf interactome in mouse hippocampal neuronal cells. J Proteomics. 2011;74:186-198.
78. Nikolsky Y, Nikolskaya T, Bugrim A. Biological networks and analysis of experimental data in drug discovery. Drug Discov Today. 2005;10:653-662.
79. Stein A, Mosca R, Aloy P. Three-dimensional modeling of protein inter-actions and complexes is going 'omics. Curr Opin Struct Biol. 2011;21:200-208.
80. Valencia A, Pazos F. Computational methods for the prediction of protein interactions. Curr Opin Struct Biol. 2002;12:368-373.
81. Weichhart T, Saemann MD. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis. 2008;67 (suppl 3):iii70-74.
82. Pilot-Storck F, Chopin E, Rual JF, et al. Interactome mapping of the phos-phatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor. Mol Cell Proteomics. 2010;9:1578-1593.
83. Jia P, Kao CF, Kuo PH, Zhao Z. A comprehensive network and pathway analysis of candidate genes in major depressive disorder. BMC Syst Biol. 2011;5 Suppl 3:S12.
84. Sperner-Unterweger B, Kohl C, Fuchs D. Immune changes and neuro-transmitters: Possible interactions in depression? Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:268-276.
85. Martins-de-Souza D. Proteomics is not only a biomarker discovery tool. Proteomics Clin Appl. 2009;3:1136-1139.
86. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-pro-tein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41(Database issue):D808-815.
87. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27:431-432.
88. Schrattenholz A, Groebe K, Soskic V. Systems biology approaches and tools for analysis of interactomes and multi-target drugs. Methods Mol Biol. 2010;662:29-58.
89. Turck CW, Iris F. Proteome-based pathway modelling of psychiatric dis-orders. Pharmacopsychiatry. 2011;44(suppl 1):S54-61.
90. Filiou MD, Turck CW, Martins-de-Souza D. Quantitative proteomics for investigating psychiatric disorders. Proteomics Clin Appl. 2011;5:38-49.
91. Gormanns P, Mueller NS, Ditzen C, Wolf S, Holsboer F, Turck CW. Phenome-transcriptome correlation unravels anxiety and depression related pathways. J Psychiatr Res. 2011;45:973-979.
92. Yang Y, Yang D, Tang G, et al. Proteomics reveals energy and glutathione metabolic dysregulation in the prefrontal cortex of a rat model of depression. Neuroscience. 2013;247:191-200.
93. Bisgaard CF, Bak S, Christensen T, Jensen ON, Enghild JJ, Wiborg O. Vesicular signalling and immune modulation as hedonic fingerprints: pro-teomic profiling in the chronic mild stress depression model. J Psychopharmacol. 2012;26:1569-1583.
94. Xu Z, Hou B, Zhang Y, et al. Antidepressive behaviors induced byenriched environment might be modulated by glucocorticoid levels. Eur Neuropsychopharmacol. 2009;19:868-875.
95. Carboni L. Peripheral biomarkers in animal models of major depressive disorder. Dis Markers. 2013;35:8.
96. Connolly KR, Thase ME. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs. 2012;17:105-126.
97. Martins-de-Souza D. Biomarkers for psychiatric disorders: where are we standing? Dis Markers. 2013;35:1-2.
98. Domenici E, Wille DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control col-lections. PLoS One. 2010;5:e9166.
99. Raedler TJ, Wiedemann K. CSF-studies in neuropsychiatric disorders. Neuro Endocrinol Lett. 2006;27:297-305.
100. Bahn S, Schwarz E, Harris LW, Martins-de-Souza D, Rahmoune H, Guest PC. Biomarker blood tests for diagnosis and management of mental disorders: focus on schizophrenia. Rev Psiq Clín. 2013;40:7.